Sutimlimab (Enjaymo)
Revision as of 10:33, 5 November 2022 by Jwarner (talk | contribs) (→Diseases for which it is used)
Mechanism of action
Anti-C1s antibody
Diseases for which it is used
History of changes in FDA indication
- 2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)
Also known as
- Code name: BIVV009
- Generic name: sutimlimab-jome
- Brand name: Enjaymo